REMARKS

The Rejection Under 35 USC § 103

Even though not necessary to overcome the rejections, the claims are narrowed to achieve an expeditious allowance.

The Office Action alleges that all the claims are obvious over the combination of Brown in view of Smith.

Brown has been extensively discussed in previous responses.

Smith is alleged to teach substituted pentacene compounds for use in the layer formulation of Brown. Smith does not teach any pentacene compound of the present claims. All of the compounds taught by Smith have substituents only on terminal rings of the pentacene and no substituents on the remaining rings. See, for example, the paragraph bridging pages 2 and 3 teaching that "the <u>substituent(s)</u> each being bonded to at least one carbon atom of a <u>terminal ring of pentacene</u> (that is, a carbon atom selected from the number 1, 2, 3, 4, 8, 9, 10, and 11 carbon atoms of pentacene) and <u>being the only substituent(s)</u> (that is, <u>hydrogen is bonded to the carbon atoms of the non-terminal rings</u>, as well as to any carbon atom of a terminal ring that does not bear a substituent)." Emphasis added.

For example, in claim 2, formula 1, does not contain any substituent on a terminal ring of pentacene, which is a requirement of Smith. See, e.g., page 3, lines 2-3.

Also in claim 2, formula 8, and likewise in claims 23-26 and 28, formulae 1-3, all contain substituents on the center ring of the pentacene. This is also contrary to the teachings of Smith, which requires that the substituents be all on the terminal rings, these substituents being the "only substituents." See, e.g., page 3, lines 4-5.

Additional dependent claims are added, all of which are patentable for at least the reasons discussed above.

Reconsideration is respectfully and courteously requested.

Amendments

TopasTM (all grades) in table 3 in the specification is now identified by its generic identity, cyclic olefin copolymer, which is well known in the art and readily available information.

Support for the amendment, e.g., of claim 17, and for the new claims can be found, e.g., on (claims 17 and 45) page 28, lines 28-33 and page 33, lines 12-27, (claim 29) page 9, lines 31-32, (claims 30 and 31) page 19, lines 20-34, (claim 32) page 20, lines 14-29 and page

21, (claim 33) page 14, lines 18-22, (claim 34) page 15, lines 21-23, (claim 35) page 15, lines 26-29, (claims 36 and 37) Table 2 and Table 3 on page 26 and 27, and page 26, line 9 and page 27, lines 10-14, (claims 38 and 39) page 28, lines 1-10, (claim 40) page 33, lines 38-39, (claim 41) page 33, lines 39-40, (claim 42) page 34, lines 2-6, (claim 43) page 31, lines 10-15, and (claim 44) page 32, lines 30-35.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/Csaba Henter/

Csaba Henter, Reg. No. 50,908 Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Boulevard, Suite 1400 Arlington, Virginia 22201 Direct Dial: 703-812-5331

Facsimile: 703-243-6410

Filed: April 16, 2010

K:\MERCK\3000 - 3999\3181\REPLY APR 10.DOC